Physician profile
Digant Bhatt
NPI 1902045495
$8,974.50
in general payments reported to CMS, 2019-2025
26 companies · $175 in 2025
The $175 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $550 · 2020: $249 · 2021: $4,065 · 2022: $2,394 · 2023: $709 · 2024: $833 · 2025: $175.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,607 · Education: $109.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,606.96 |
| Education | $109.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $5,718.42 | 2019-2025 | Lifevest |
| Novartis Pharmaceuticals Corporation | $662.46 | 2019-2024 | |
| Pfizer INC. | $408.44 | 2019-2024 | |
| Janssen Pharmaceuticals, INC | $321.93 | 2019-2023 | Xarelto |
| Actelion Pharmaceuticals US, INC. | $214.03 | 2020-2025 | Opsumit, Uptravi |
| Cvrx, INC. | $162.65 | 2024 | Barostim Neo System |
| Bayer Healthcare Pharmaceuticals INC. | $162.27 | 2019-2024 | |
| Heartflow, INC. | $162.03 | 2024 | |
| Abbott Laboratories | $159.93 | 2023-2024 | Mitraclip, Assurity, Cardiomems |
| Astrazeneca Pharmaceuticals Lp | $144.44 | 2019-2023 | |
| Merck Sharp & Dohme LLC | $104.18 | 2022-2024 | Verquvo |
| E.R. Squibb & Sons, L.L.C. | $89.30 | 2020-2024 | Eliquis, Camzyos |
| Amgen INC. | $88.33 | 2019-2024 | Repatha |
| Medtronic, INC. | $85.51 | 2021-2023 | Onyx Frontier |
| Boston Scientific Corporation | $69.57 | 2019-2023 | Watchman Access System |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lexicon Pharmaceuticals, INC. | $66.23 | 2023-2024 | Inpefa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $62.88 | 2022 | |
| United Therapeutics Corporation | $54.85 | 2024 | Tyvaso |
| Philips North America LLC | $45.35 | 2019 | |
| W. L. Gore & Associates, INC. | $40.74 | 2019-2020 | |
| Abiomed | $37.79 | 2022 | |
| Esperion Therapeutics, INC. | $34.32 | 2024 | Nexletol |
| Novo Nordisk INC | $30.24 | 2025 | Rybelsus, Ozempic |
| Inari Medical, INC. | $17.37 | 2024 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Amarin Pharma, INC. | $17.22 | 2020 | |
| Edwards Lifesciences Corporation | $14.02 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Digant Bhatt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.